Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Study
Classic

The costs of adverse drug events in hospitalized patients.

Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277(4):307-11.

Save
Print
March 27, 2005
Bates DW, Spell N, Cullen DJ, et al. JAMA. 1997;277(4):307-11.
View more articles from the same authors.

The authors report the economic analysis of their study of adverse drug events (ADEs) at the Massachusetts General Hospital and Brigham and Women’s Hospital in Boston. Using a case-control design, the authors examine the direct costs to the hospital of preventable and nonpreventable ADEs. Although some results did not achieve statistical significance and others did so marginally, the authors demonstrate an increased length of stay and associated hospital charges in the ADE group relative to the controls and in the cases and controls relative to the remainder of the study cohort. While cautioning about the generalizability of their results, the authors estimate a national cost figure of $4 billion (in 1997) for all ADEs and $2 billion for preventable events. This detailed analysis continues to serve as an important reference to motivate policy and institutional investment in systems intended to prevent ADEs.

Save
Print
Cite
Citation

Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277(4):307-11.

Related Resources From the Same Author(s)
Related Resources